ATRION Co. (NASDAQ:ATRI) Position Lessened by Thrivent Financial For Lutherans

Thrivent Financial For Lutherans trimmed its position in shares of ATRION Co. (NASDAQ:ATRI) by 24.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,841 shares of the medical instruments supplier’s stock after selling 2,251 shares during the quarter. Thrivent Financial For Lutherans owned about 0.37% of ATRION worth $4,314,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of ATRI. State Street Corp increased its holdings in shares of ATRION by 3.0% during the second quarter. State Street Corp now owns 31,790 shares of the medical instruments supplier’s stock valued at $20,446,000 after acquiring an additional 919 shares in the last quarter. First Trust Advisors LP acquired a new position in ATRION in the 3rd quarter worth approximately $1,740,000. Raymond James Financial Services Advisors Inc. increased its holdings in ATRION by 6.0% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 2,684 shares of the medical instruments supplier’s stock worth $1,804,000 after buying an additional 152 shares during the period. American Century Companies Inc. purchased a new stake in ATRION in the 3rd quarter worth approximately $1,094,000. Finally, Advisor Group Inc. boosted its position in ATRION by 5,826.7% in the 3rd quarter. Advisor Group Inc. now owns 889 shares of the medical instruments supplier’s stock worth $598,000 after purchasing an additional 874 shares in the last quarter. Hedge funds and other institutional investors own 59.05% of the company’s stock.

How to Become a New Pot Stock Millionaire

Separately, BidaskClub lowered ATRION from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th.

Shares of NASDAQ:ATRI traded down $7.00 during midday trading on Friday, reaching $602.00. 10,228 shares of the company’s stock traded hands, compared to its average volume of 10,514. The firm has a market capitalization of $1,114.48, a price-to-earnings ratio of 32.56 and a beta of 0.67. ATRION Co. has a 1 year low of $460.15 and a 1 year high of $694.00.

ATRION (NASDAQ:ATRI) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share for the quarter. ATRION had a return on equity of 19.53% and a net margin of 24.96%. The company had revenue of $34.02 million for the quarter.

The business also recently announced a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Thursday, March 15th were paid a $1.20 dividend. This represents a $4.80 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend was Wednesday, March 14th.

TRADEMARK VIOLATION WARNING: “ATRION Co. (NASDAQ:ATRI) Position Lessened by Thrivent Financial For Lutherans” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/thrivent-financial-for-lutherans-lowers-stake-in-atrion-co-atri.html.

ATRION Company Profile

Atrion Corp. engages in the manufacture and development of products for medical applications. It involves in the marketing of components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It specializes in the fluid delivery, as well as ophthalmic and cardiovascular devices.

Institutional Ownership by Quarter for ATRION (NASDAQ:ATRI)

Receive News & Ratings for ATRION Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATRION and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply